Bitterroot Bio website screenshot

Bitterroot Bio

Bitterroot Bio is a privately held, clinical-stage biotechnology company based in Palo Alto, California, pioneering the emerging field of cardio-immunology — the interplay between the immune system and cardiovascular disease. Its lead program, BRB-002, is a novel investigational immunomodulating protein therapy that targets CD47 to treat atherosclerotic cardiovascular disease (ASCVD) by acting on atherosclerotic plaque through the immunomodulation of macrophages, an approach distinct from current standards of care. Founded in 2021, the company is advancing BRB-002 through its MATADOR Phase 2a proof-of-concept study. Bitterroot Bio is a therapeutics developer and publishes no public developer API or programmatic surface; this profile captures its public web identity within the API Evangelist network.

Bitterroot Bio is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Cardiovascular, and Cardio-Immunology.

Bitterroot Bio’s developer surface includes engineering blog and 5 more developer resources.

🌐 Visit website 📡 Source on GitHub
9.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyLife SciencesBiotechnologyCardiovascularCardio-ImmunologyPharmaceuticalsClinical TrialsDrug DevelopmentPalo Alto

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 9.5/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Access Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/bitterroot-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Bitterroot Bio Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 3

The organization behind the API

Website
Website
 Blog
Blog
 LinkedIn
LinkedIn

Source (apis.yml)

apis.yml Raw ↑ 
aid: bitterroot-bio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/bitterroot-bio.png
name: Bitterroot Bio
description: Bitterroot Bio is a privately held, clinical-stage biotechnology company based in Palo Alto, California, pioneering
  the emerging field of cardio-immunology — the interplay between the immune system and cardiovascular disease. Its lead program,
  BRB-002, is a novel investigational immunomodulating protein therapy that targets CD47 to treat atherosclerotic cardiovascular
  disease (ASCVD) by acting on atherosclerotic plaque through the immunomodulation of macrophages, an approach distinct from
  current standards of care. Founded in 2021, the company is advancing BRB-002 through its MATADOR Phase 2a proof-of-concept
  study. Bitterroot Bio is a therapeutics developer and publishes no public developer API or programmatic surface; this profile
  captures its public web identity within the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/bitterroot-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Life Sciences
- Biotechnology
- Cardiovascular
- Cardio-Immunology
- Pharmaceuticals
- Clinical Trials
- Drug Development
- Palo Alto
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://brbio.com
- type: Blog
  url: https://brbio.com/category/press-release/
- type: PrivacyPolicy
  url: https://brbio.com/privacy-policy/
- type: TermsOfService
  url: https://brbio.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/bitterroot-bio
- type: DomainSecurity
  url: security/bitterroot-bio-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence